GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $3,331,172.92 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 35,506 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the completion of the transaction, the chief financial officer now directly owns 2,472 shares in the company, valued at approximately $231,923.04. The trade was a 93.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Stock Down 7.4 %

WGS traded down $7.19 on Friday, hitting $89.38. 725,309 shares of the company were exchanged, compared to its average volume of 909,701. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock’s fifty day moving average is $78.01 and its 200-day moving average is $53.19. The company has a market cap of $2.46 billion, a PE ratio of -28.74 and a beta of 2.02. GeneDx Holdings Corp. has a 12 month low of $2.85 and a 12 month high of $98.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.82) EPS. Equities research analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on WGS. TD Cowen boosted their target price on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company boosted their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, Craig Hallum boosted their price target on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $70.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company’s stock worth $2,214,000 after purchasing an additional 44,889 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of GeneDx in the third quarter valued at approximately $604,000. Franklin Resources Inc. bought a new stake in GeneDx in the 3rd quarter valued at $301,000. Tidal Investments LLC bought a new position in GeneDx during the third quarter worth $514,000. Finally, Barclays PLC increased its holdings in shares of GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.